{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:32:36Z","timestamp":1787758356114,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Due to the contradictory results of the effects of Vitamin B6 in reducing the hematotoxic effects of linezolid, the present study aimed to investigate the possible role of Vitamin B6 administration in reducing linezolid-related hematological toxicities in patients with chronic osteomyelitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      In a randomized double-blind placebo-controlled clinical trial, patients with chronic osteomyelitis were randomly divided into two groups (n = 40 each): the intervention group received Vitamin B\n                      <jats:sub>6<\/jats:sub>\n                      40 mg twice daily from the beginning of treatment with linezolid and the control group received placebo with linezolid, both for 21 days. Blood variables including hemoglobin (Hb), white blood cells (WBC), and platelets (PLT) were measured at baseline and at the end of the 1\n                      <jats:sup>st<\/jats:sup>\n                      , 2\n                      <jats:sup>nd<\/jats:sup>\n                      , and 3\n                      <jats:sup>rd<\/jats:sup>\n                      weeks (days 7, 14, and 21) of the intervention.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There was no significant difference between the groups regarding the count of WBC and PLT and level of Hb at evaluated time points. Furthermore, there was a significant decreasing trend in all parameters within both groups; however, the decreasing trend of both PLT and WBC was slower in the intervention (Vitamin B6) group compared to the placebo group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Vitamin B6 has no significant effect in the reduction of hematological adverse effects of linezolid in chronic osteomyelitis patients. However, it could retard the decreasing trend of WBC and PLT counts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/abr.abr_274_21","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T07:30:07Z","timestamp":1661499007000},"page":"67","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Vitamin B6 in the Prevention of Hematological Adverse Effects of Linezolid in Patients with Chronic Osteomyelitis"],"prefix":"10.4103","volume":"11","author":[{"given":"Kiana","family":"Shirani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzin","family":"Khorvash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasool","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrooz","family":"Ataie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javad","family":"Tarrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farideh","family":"Fallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-67-20240830","doi-asserted-by":"crossref","first-page":"e00932","DOI":"10.1128\/IAI.00932-19","article-title":"Staphylococcus aureus osteomyelitis: Bone, bugs, and surgery","volume":"88","author":"Urish","year":"2020","journal-title":"Infect Immun"},{"key":"R2-67-20240830","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11926-020-00928-1","article-title":"New insights into adult and paediatric chronic non-bacterial osteomyelitis CNO","volume":"22","author":"Hedrich","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"R3-67-20240830","doi-asserted-by":"crossref","first-page":"104431","DOI":"10.1016\/j.micpath.2020.104431","article-title":"A comprehensive review of bacterial osteomyelitis with emphasis on Staphylococcus aureus","volume":"148","author":"Nasser","year":"2020","journal-title":"Microb Pathog"},{"key":"R4-67-20240830","doi-asserted-by":"crossref","first-page":"16107","DOI":"10.1038\/s41598-020-73108-x","article-title":"Association of mprF mutations with cross-resistance to daptomycin and vancomycin in Methicillin-Resistant Staphylococcus aureus (MRSA)","volume":"10","author":"Thitiananpakorn","year":"2020","journal-title":"Sci Rep"},{"key":"R5-67-20240830","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: A review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"R6-67-20240830","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jac\/dkw450","article-title":"Linezolid: A promising option in the treatment of Gram-positives","volume":"72","author":"Zahedi Bialvaei","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R7-67-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diagmicrobio.2019.03.006","article-title":"A selective culture medium for screening linezolid-resistant gram-positive bacteria","volume":"95","author":"Nordmann","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R8-67-20240830","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1515\/jbcpp-2020-0468","article-title":"Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy","volume":"32","author":"Pratama","year":"2021","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"R9-67-20240830","first-page":"e10890","article-title":"Reversible myelosuppresion with prolonged usage of linezolid in treatment of methicillin-resistant Staphylococcus aureus","volume":"12","author":"Sharma","year":"2020","journal-title":"Cureus"},{"key":"R10-67-20240830","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jsps.2019.09.002","article-title":"Determining therapeutic trough ranges for linezolid","volume":"27","author":"Alsultan","year":"2019","journal-title":"Saudi Pharm J"},{"key":"R11-67-20240830","first-page":"470","article-title":"Linezolid-related adverse effects in clinical practice in children","volume":"115","author":"Bayram","year":"2017","journal-title":"Arch Argent Pediatr"},{"key":"R12-67-20240830","first-page":"133","article-title":"Real-life frequency of new-onset thrombocytopenia during linezolid treatment","volume":"72","author":"Giunio-Zorkin","year":"2019","journal-title":"Can J Hosp Pharm"},{"key":"R13-67-20240830","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1086\/508280","article-title":"No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment","volume":"43","author":"Plachouras","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R14-67-20240830","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/jac\/dkh405","article-title":"Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6","volume":"54","author":"Spellberg","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R15-67-20240830","first-page":"401","article-title":"Successful treatment of X-linked sideroblastic anemia with ALAS2 R452H mutation using vitamin B6","volume":"59","author":"Kawakami","year":"2018","journal-title":"Rinsho Ketsueki"},{"key":"R16-67-20240830","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.curtheres.2012.12.002","article-title":"Effects of vitamin B6 therapy for sepsis patients with linezolid-associated cytopenias: A retrospective study","volume":"74","author":"Deng","year":"2013","journal-title":"Curr Ther Res Clin Exp"},{"key":"R17-67-20240830","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/jac\/dkm506","article-title":"The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer","volume":"61","author":"Youssef","year":"2008","journal-title":"J Antimicrob Chemother"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_274_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:11:08Z","timestamp":1787757068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_274_21"}},"subtitle":["A Randomized Double-Blind Placebo-Controlled Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/abr.abr_274_21","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}